Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS)
- PMID: 16154669
- DOI: 10.1016/j.vaccine.2005.07.069
Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS)
Abstract
The preparation of recombinant hepatitis B vaccines involves using cellular cultures of Saccharomyces cerevisiae, otherwise known as baker's yeast. Prior to vaccine licensure, clinical trials were performed to address whether residual yeast proteins in the vaccines could induce anaphylaxis, including testing for IgE anti-yeast antibody levels. 1-2% of subjects had anti-yeast IgE antibodies before immunization, but demonstrated no significant rise in IgE after HBV. We searched reports in the Vaccine Adverse Event Reporting System (VAERS) for those that mentioned a history of allergy to yeast and then reviewed the adverse events described in these reports for potential anaphylactic reactions. Probable anaphylaxis was defined as the presence of one or more dermatologic symptoms and one or more respiratory, gastrointestinal, or cardiovascular symptoms with onset within 4 h of Hepatitis B vaccination. Possible anaphylaxis was defined in one of two ways: (1) cases that described dermatologic or respiratory symptoms (but not both) occurring within 4h of vaccination; or (2) cases that described one or more dermatologic and/or respiratory symptoms occurring 4-12 h post vaccination. Among the 107 reports of pre-existing "yeast allergies," 11 reports described probable or possible anaphylaxis after HBV. Four additional cases were described after other vaccines. The majority of vaccinees who met the case definitions and had a history of yeast allergies were female, ages ranged from 10 to 64, and symptom onset ranged from 15 min to 5 h after vaccination. No deaths were reported. The small number of reports to VAERS may be partly due to health care professionals observing current contraindications by not vaccinating yeast sensitive individuals. Nevertheless, yeast associated anaphylaxis after HBV in sensitized patients appears to be a rare event.
Similar articles
-
Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.Vaccine. 2008 May 2;26(19):2428-32. doi: 10.1016/j.vaccine.2008.02.052. Epub 2008 Mar 17. Vaccine. 2008. PMID: 18406499 Review.
-
Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.Vaccine. 2008 Feb 26;26(9):1166-72. doi: 10.1016/j.vaccine.2007.12.049. Epub 2008 Jan 22. Vaccine. 2008. PMID: 18255204 Review.
-
Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.Pediatrics. 2005 Feb;115(2):453-60. doi: 10.1542/peds.2004-1519. Pediatrics. 2005. PMID: 15687455
-
Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitis.J Rheumatol. 2004 Nov;31(11):2181-8. J Rheumatol. 2004. PMID: 15517631
-
Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):825-40. doi: 10.1002/pds.936. Pharmacoepidemiol Drug Saf. 2004. PMID: 15386719 Review.
Cited by
-
Allergic Reactions to Vaccines in Children: From Constituents to Specific Vaccines.Biomedicines. 2023 Feb 18;11(2):620. doi: 10.3390/biomedicines11020620. Biomedicines. 2023. PMID: 36831156 Free PMC article. Review.
-
Anaphylaxie auf Zusatzstoffe in Impfstoffen.Allergo J. 2022;31(5):22-39. doi: 10.1007/s15007-022-5054-3. Epub 2022 Jul 25. Allergo J. 2022. PMID: 35911653 Free PMC article. Review. German.
-
Anaphylaxis to additives in vaccines.Allergo J Int. 2022;31(5):123-136. doi: 10.1007/s40629-022-00215-8. Epub 2022 Jun 14. Allergo J Int. 2022. PMID: 35729887 Free PMC article. Review.
-
Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines.Saudi Pharm J. 2022 Feb;30(2):180-184. doi: 10.1016/j.jsps.2021.12.008. Epub 2021 Dec 31. Saudi Pharm J. 2022. PMID: 35002372 Free PMC article.
-
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.Allergy. 2021 Jun;76(6):1640-1660. doi: 10.1111/all.14840. Epub 2021 Jun 4. Allergy. 2021. PMID: 33811364 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous